Common Cold Can Be Dangerous After Bone Marrow Transplant
TUESDAY, March 21, 2017 -- The common cold can be deadly for patients recovering from bone marrow transplants, a new study warns.
After a bone marrow transplant, patients have weakened immune systems. This puts them at risk for infections that... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 21, 2017 Category: Journals (General) Source Type: news
Common Cold Can Be Dangerous After Bone Marrow Transplant
Rhinovirus far more worrisome in those with weakened immune systems, researchers say (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - March 20, 2017 Category: Respiratory Medicine Authors: webmaster at doctorslounge.com Tags: Family Medicine, Infections, Nursing, Pulmonology, Research, Immunology, News, Source Type: news
Rare cancer sufferer Daryl Allinson saved by crowdfunders
Daryl Allinson, 13, from Frome, Somerset, was struck down with a strain of leukaemia in 2015 but went into remission thanks to a bone marrow transplant from his brother. (Source: the Mail online | Health)
Source: the Mail online | Health - March 6, 2017 Category: Consumer Health News Source Type: news
Gamida Cell touts first patient treated in Phase III NiCord trial
Gamida Cell said today that the 1st patient has been treated in the Phase III registration trial of its NiCord cell graft for patients with blood cancer. The treatment is a graft derived from umbilical cord blood which has been expanded and enriched with stem and progenitor cells, according to the company.
The Jerusalem-based company’s cell graft was designed as an alternative to bone marrow transplantation for patients with blood cancer who do not have a fully matched donor.
Get the full story at our sister site, Drug Delivery Business News.
The post Gamida Cell touts first patient treated in Phase III NiCord tria...
Source: Mass Device - February 28, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Clinical Trials Food & Drug Administration (FDA) Oncology Research & Development Gamida Cell Source Type: news
Merck ’s letermovir meets primary endpoint in Phase III trial to prevent CMV infection
Healthcare firm Merck has reported positive results from the Phase III clinical trial of anti-viral drug letermovir to prevent cytomegalovirus (CMV) infection in recipients of bone marrow transplant. (Source: Drug Development Technology)
Source: Drug Development Technology - February 28, 2017 Category: Pharmaceuticals Source Type: news
Merck ’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Dateline City:
KENILWORTH, N.J. Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017KENILWORTH, N.J.--(BUSINESS WIRE)--Merck& Co., Inc. (NYSE:MRK), known as MSD outside the United States and
Canada, today announced results of the pivotal Phase 3 clinical study of
letermovir, an investigational antiviral medicine for the prevention of
clinically-significant cytomegalovirus (CMV) infection in adult (18
years and older) CMV-seropositive recipients of an allogenei...
Source: Merck.com - Research and Development News - February 26, 2017 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News #Merck #MRK $MRK Letermovir MSD NYSE:MRK Source Type: news
Merck drug prevents serious infection after marrow transplant: study
(Reuters) - An experimental Merck& Co drug succeeded in preventing clinically serious cytomegalovirus (CMV) following bone marrow transplant and was associated with a lower death rate compared with placebo in a late state study, the company said. (Source: Reuters: Health)
Source: Reuters: Health - February 23, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
43rd Annual Meeting of the European Society for Blood and Marrow Transplantation
(European Society for Blood and Marrow Transplantation) During its 43rd Annual Meeting, the EBMT will acknowledge the work that stems from the pioneering observations made by E. Donnall Thomas, also known as the father of bone marrow transplantation. At the Opening Session, Rainer Storb from the faculty of both, the Fred Hutchinson Cancer Research Center and the University of Washington School of Medicine, will give a keynote lecture entitled, '60 years of HSCT: progress from bone marrow transplantation to the first cellular and gene therapies.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 23, 2017 Category: Cancer & Oncology Source Type: news
Toddler with leukaemia is saved by designer immune cells
One-year-old Layla was diagnosed when she was just 14 weeks old. Chemotherapy and bone marrow transplant failed to halt the aggressive disease. She was taken to Great Ormond Street. (Source: the Mail online | Health)
Source: the Mail online | Health - February 19, 2017 Category: Consumer Health News Source Type: news
A 60-Year-Old Man With Progressive Anemia While Receiving Checkpoint Blockade Therapy for Relapsed Myelofibrosis
A 60-year-old man with a history of coronary artery disease and JAK2 V617F –positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias. (Source: CancerNetwork)
Source: CancerNetwork - February 15, 2017 Category: Cancer & Oncology Authors: Aaron M. Goodman, MD Caitlin Costello, MD Edward D. Ball, MD Megan Rust, MD Tags: Case Studies Hematologic Malignancies Oncology Journal Source Type: news
Algorithm Predicts Severe GVHD After Bone Marrow Transplant Algorithm Predicts Severe GVHD After Bone Marrow Transplant
A blood test performed 7 days after bone marrow transplant may predict serious, life-threatening GVHD and allow early intervention.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 9, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Doctors create 'MAGIC algorithm' to predict bone marrow transplant patients' risk of dying
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Researchers at Mount Sinai Health System have discovered a way to predict whether blood cancer patients who received a bone marrow transplant will develop graft-versus-host disease, a common and often lethal complication, according to a study published in JCI (The Journal of Clinical Investigation) Insight. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 9, 2017 Category: Cancer & Oncology Source Type: news
Sixteen aplastic anemia patients free of disease after bone marrow transplant and chemo
Physicians report they have successfully treated 16 patients with a rare and lethal form of bone marrow failure called severe aplastic anemia using partially matched bone marrow transplants followed by two high doses of a common chemotherapy drug. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 7, 2017 Category: Science Source Type: news
16 aplastic anemia patients free of disease after bone marrow transplant and chemo
(Johns Hopkins Medicine) Physicians at the Johns Hopkins Kimmel Cancer Center report they have successfully treated 16 patients with a rare and lethal form of bone marrow failure called severe aplastic anemia using partially matched bone marrow transplants followed by two high doses of a common chemotherapy drug. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 7, 2017 Category: Cancer & Oncology Source Type: news
Health Care Special Report: Children ’s Mercy platform targets ‘Goldilocks’ doses
For some treatments, the perfect dose is a necessity. Leukemia patients, for example, take busulfan to prepare for a bone marrow transplant. Too little, and the patient ’s body won’t accept the transplant. Too much, however, can cause irreversible liver damage.
“It’s a really fine line,” said Susan Abdel-Rahman, director of the pharmacokinetic and pharmacodynamics core laboratory at Children’s Mercy.
She created a platform to help determine how much i s “just right” based on a child’s… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 3, 2017 Category: Pharmaceuticals Authors: Elise Reuter Source Type: news
